Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 13/20 | 0.71 |
| ▸ | NMUR1 | Q9HB89 | 12/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539226 | 1.00 | NMUR2 (0.71) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL29698606 | 1.00 | NMUR2 (0.71) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL29604581 | 0.97 | NMUR2 (0.77) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL29464559 | 0.89 | NMUR2 (0.68) | NMUR2NMUR1 | |
| SCHEMBL29604784 | 0.89 | OPRM1 (0.63) | NMUR2NMUR1OPRK1OPRM1 | |
| SCHEMBL29519178 | 0.89 | NMUR2 (0.79) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL29679668 | 0.86 | SLC6A2 (0.61) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL22620441 | 0.85 | OPRK1 (0.61) | NMUR2NMUR1OPRD1OPRK1OPRM1 | |
| SCHEMBL29430579 | 0.85 | NMUR2 (0.62) | NMUR2NMUR1 | |
| SCHEMBL29973451 | 0.85 | NMUR2 (0.60) | NMUR2NMUR1OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| EP-4642761-A1 | BIOREACTIVE PROTEINS CONTAINING AN UNNATURAL AMINO ACID AND ARGININE | The Regents of University of California (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4612127-A1 | BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | claimed |
| WO-2025081091-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4496837-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2025-01-29 | — | — | EP | claimed |
| EP-4486366-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2025-01-08 | — | — | EP | claimed |
| CN-119213061-A | Cross-linked protein, method for producing the same and use thereof | 纽约州立大学研究基金会 | 2024-12-27 | — | — | CN | claimed |
| CN-115993643-A | Three-dimensional earthquake imaging point spread function calculation method | 中国石油化工股份有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115925801-A | Heteropolypeptide based on small-molecule opium and neuropeptide FF as well as preparation and application thereof | 兰州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115835876-A | Use of neuropeptides for the treatment of bone injury disorders | 深圳先进技术研究院 | 2023-03-21 | — | — | CN | claimed |
| WO-2022261235-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022261221-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022232377-A2 | BIOREACTIVE PROTEINS CONTAINING UNNATURAL AMINO ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-03 | — | — | WO | claimed |
| CN-115232201-A | PrRP31 modified by polyethylene glycol and preparation and application thereof | 西北工业大学 | 2022-10-25 | — | — | CN | claimed |
| WO-2022187273-A1 | BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-09 | — | — | WO | claimed |
| CN-114730607-A | Memory fault repairing method and device | 华为技术有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220038250-A1 | Design Simplification For Distributed-Tone Resource Units In 6GHz Low-Power Indoor Systems | MEDIATEK SINGAPORE PTE. LTD. (SG) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127908-A1 | HETEROBIFUNCTIONAL CONDITIONAL INHIBITORS | BRDT, NFKBIA, SSB | NMUR2 3310/4885NMUR1 3346/4885OPRD1 3442/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | NMUR2 3891/4885NMUR1 3149/4885OPRD1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.